Cargando…
Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine
BACKGROUND: Active immunization with the BNT162b2 vaccine (Pfizer–BioNTech) has been a critical mitigation tool against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection during the coronavirus disease 2019 (Covid-19) pandemic. In light of reports of waning protection occurring 6...
Autores principales: | Moreira, Edson D., Kitchin, Nicholas, Xu, Xia, Dychter, Samuel S., Lockhart, Stephen, Gurtman, Alejandra, Perez, John L., Zerbini, Cristiano, Dever, Michael E., Jennings, Timothy W., Brandon, Donald M., Cannon, Kevin D., Koren, Michael J., Denham, Douglas S., Berhe, Mezgebe, Fitz-Patrick, David, Hammitt, Laura L., Klein, Nicola P., Nell, Haylene, Keep, Georgina, Wang, Xingbin, Koury, Kenneth, Swanson, Kena A., Cooper, David, Lu, Claire, Türeci, Özlem, Lagkadinou, Eleni, Tresnan, Dina B., Dormitzer, Philip R., Şahin, Uğur, Gruber, William C., Jansen, Kathrin U. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Massachusetts Medical Society
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9006787/ https://www.ncbi.nlm.nih.gov/pubmed/35320659 http://dx.doi.org/10.1056/NEJMoa2200674 |
Ejemplares similares
-
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
por: Polack, Fernando P., et al.
Publicado: (2020) -
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months
por: Thomas, Stephen J., et al.
Publicado: (2021) -
SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3
por: Falsey, Ann R., et al.
Publicado: (2021) -
Efficacy and safety of the BNT162b2 mRNA COVID-19 vaccine in participants with a history of cancer: subgroup analysis of a global phase 3 randomized clinical trial
por: Thomas, Stephen J., et al.
Publicado: (2022) -
Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents
por: Frenck, Robert W., et al.
Publicado: (2021)